Abstract
Background: To assess the oncologic outcomes of hypofractionated whole breast irradiation (Hypo-WBI). Methods: Eligible patients had undergone breast conservative surgery for early breast cancer (pTis-2) and none/limited nodal involvement. Hypo-WBI consisted of 34 Gy in 10 daily fractions over 2 weeks to the whole breast three-dimensional conformal radiotherapy (3DCRT), followed by a single fraction of 8 Gy to the tumor bed after 1 week (electrons). Primary endpoint is freedom from ipsilateral breast tumor recurrence (IBTR). Minimum follow up for living & event-free patients is 3 yrs.; median follow up time of the whole analyzed patient population is 5.4 yrs. (range: 1.8-11.4 yrs). Results: Two hundred fifty-one patients were accrued from 2004 to 2013. All patients underwent local excision of the primary tumor to negative margins. Four patients failed in the ipsilateral breast after a median time of 3.2 years (range: 1.7-5.7 yrs) for a 5-year IBTR-free survival of 98.7% (95%CI: 97.3%-100%). IBTR-free survival was significantly higher for patients with invasive cancer than for patients with intraductal carcinoma (p = 0.036). Within patients with invasive tumors, no clear trends or associations were detected between IBTR and age, grading, molecular subtype, pT or pN stage. At 5 years, the actuarial rates of GR2 fibrosis and GR2+ teleangectasia are 2.4% (95%CI: 0-6.5%) and 7.1% (95%CI: 0.4-13.7%), respectively. Cosmesis was scored as excellent/good by ≈95% of patients and ≈60% of clinicians. Conclusions: Hypo-WBI in 3 weeks allows excellent oncologic outcomes for invasive breast cancer after conservative surgery. Patients with intraductal carcinoma should be treated with Hypo-WBI only within a controlled study. Trial registration: IRE-IFO Ethical and Scientific Committee (cod. RS61/04).
| Original language | English |
|---|---|
| Article number | 191 |
| Journal | Journal of Experimental and Clinical Cancer Research |
| Volume | 36 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Dec 27 2017 |
Fingerprint
Keywords
- Breast carcinoma in situ
- Breast neoplasms
- Dose hypofractionation
- Local neoplasm recurrence
- Radiotherapy
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Short course hypofractionated whole breast irradiation after conservative surgery : A single institution phase II study. / Pinnarò, Paola; Giordano, Carolina; Farneti, Alessia; Faiella, Adriana; Iaccarino, Giuseppe; Landoni, Valeria; Giannarelli, Diana; Vici, Patrizia; Strigari, Lidia; Sanguineti, Giuseppe.
In: Journal of Experimental and Clinical Cancer Research, Vol. 36, No. 1, 191, 27.12.2017.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Short course hypofractionated whole breast irradiation after conservative surgery
T2 - A single institution phase II study
AU - Pinnarò, Paola
AU - Giordano, Carolina
AU - Farneti, Alessia
AU - Faiella, Adriana
AU - Iaccarino, Giuseppe
AU - Landoni, Valeria
AU - Giannarelli, Diana
AU - Vici, Patrizia
AU - Strigari, Lidia
AU - Sanguineti, Giuseppe
PY - 2017/12/27
Y1 - 2017/12/27
N2 - Background: To assess the oncologic outcomes of hypofractionated whole breast irradiation (Hypo-WBI). Methods: Eligible patients had undergone breast conservative surgery for early breast cancer (pTis-2) and none/limited nodal involvement. Hypo-WBI consisted of 34 Gy in 10 daily fractions over 2 weeks to the whole breast three-dimensional conformal radiotherapy (3DCRT), followed by a single fraction of 8 Gy to the tumor bed after 1 week (electrons). Primary endpoint is freedom from ipsilateral breast tumor recurrence (IBTR). Minimum follow up for living & event-free patients is 3 yrs.; median follow up time of the whole analyzed patient population is 5.4 yrs. (range: 1.8-11.4 yrs). Results: Two hundred fifty-one patients were accrued from 2004 to 2013. All patients underwent local excision of the primary tumor to negative margins. Four patients failed in the ipsilateral breast after a median time of 3.2 years (range: 1.7-5.7 yrs) for a 5-year IBTR-free survival of 98.7% (95%CI: 97.3%-100%). IBTR-free survival was significantly higher for patients with invasive cancer than for patients with intraductal carcinoma (p = 0.036). Within patients with invasive tumors, no clear trends or associations were detected between IBTR and age, grading, molecular subtype, pT or pN stage. At 5 years, the actuarial rates of GR2 fibrosis and GR2+ teleangectasia are 2.4% (95%CI: 0-6.5%) and 7.1% (95%CI: 0.4-13.7%), respectively. Cosmesis was scored as excellent/good by ≈95% of patients and ≈60% of clinicians. Conclusions: Hypo-WBI in 3 weeks allows excellent oncologic outcomes for invasive breast cancer after conservative surgery. Patients with intraductal carcinoma should be treated with Hypo-WBI only within a controlled study. Trial registration: IRE-IFO Ethical and Scientific Committee (cod. RS61/04).
AB - Background: To assess the oncologic outcomes of hypofractionated whole breast irradiation (Hypo-WBI). Methods: Eligible patients had undergone breast conservative surgery for early breast cancer (pTis-2) and none/limited nodal involvement. Hypo-WBI consisted of 34 Gy in 10 daily fractions over 2 weeks to the whole breast three-dimensional conformal radiotherapy (3DCRT), followed by a single fraction of 8 Gy to the tumor bed after 1 week (electrons). Primary endpoint is freedom from ipsilateral breast tumor recurrence (IBTR). Minimum follow up for living & event-free patients is 3 yrs.; median follow up time of the whole analyzed patient population is 5.4 yrs. (range: 1.8-11.4 yrs). Results: Two hundred fifty-one patients were accrued from 2004 to 2013. All patients underwent local excision of the primary tumor to negative margins. Four patients failed in the ipsilateral breast after a median time of 3.2 years (range: 1.7-5.7 yrs) for a 5-year IBTR-free survival of 98.7% (95%CI: 97.3%-100%). IBTR-free survival was significantly higher for patients with invasive cancer than for patients with intraductal carcinoma (p = 0.036). Within patients with invasive tumors, no clear trends or associations were detected between IBTR and age, grading, molecular subtype, pT or pN stage. At 5 years, the actuarial rates of GR2 fibrosis and GR2+ teleangectasia are 2.4% (95%CI: 0-6.5%) and 7.1% (95%CI: 0.4-13.7%), respectively. Cosmesis was scored as excellent/good by ≈95% of patients and ≈60% of clinicians. Conclusions: Hypo-WBI in 3 weeks allows excellent oncologic outcomes for invasive breast cancer after conservative surgery. Patients with intraductal carcinoma should be treated with Hypo-WBI only within a controlled study. Trial registration: IRE-IFO Ethical and Scientific Committee (cod. RS61/04).
KW - Breast carcinoma in situ
KW - Breast neoplasms
KW - Dose hypofractionation
KW - Local neoplasm recurrence
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85040161878&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040161878&partnerID=8YFLogxK
U2 - 10.1186/s13046-017-0640-z
DO - 10.1186/s13046-017-0640-z
M3 - Article
VL - 36
JO - Journal of Experimental and Clinical Cancer Research
JF - Journal of Experimental and Clinical Cancer Research
SN - 0392-9078
IS - 1
M1 - 191
ER -